Gemcitabine: Vascular toxicity and prothrombotic potential

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 703-716

  Dasanu, Constantin A ^a  

^a NONE   (United States)

Author keywords

Capillary leak syndrome; Gemcitabine; Prothrombotic activity; Prothrombotic potential; Thrombotic microangiopathy; Vascular toxicity or events; Vasculitis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPARAGINASE; BEVACIZUMAB; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIURETIC AGENT; GEMCITABINE; IRINOTECAN; LENALIDOMIDE; MITOMYCIN C; NAVELBINE; OXYGEN; PACLITAXEL; PLATINUM COMPLEX; PREDNISONE; PROSTACYCLIN DERIVATIVE; RITUXIMAB; STEROID; TACROLIMUS; TAMOXIFEN; THALIDOMIDE; TROMETAMOL; UNINDEXED DRUG;

ACUTE DISEASE; ACUTE HEART INFARCTION; ANEMIA; ANGINA PECTORIS; ARTERY DISEASE; ARTERY THROMBOSIS; BLADDER CANCER; BONE MARROW SUPPRESSION; BRAIN DISEASE; BREAST CANCER; CANCER RADIOTHERAPY; CAPILLARY LEAK SYNDROME; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COLLAGEN DISEASE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG CLEARANCE; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EPILEPTIC STATE; ERYTHROCYTE SEDIMENTATION RATE; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; FOOT EDEMA; GANGRENE; HEART FAILURE; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPERPIGMENTATION; HYPOPROTEINEMIA; HYPOTENSION; HYPOXEMIA; ISCHEMIA; LETHARGY; LEUKOENCEPHALOPATHY; LIMB SWELLING; LIVER FAILURE; LIVER INJURY; LIVER METASTASIS; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MEDICAL RESEARCH; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INJURY; MUSCLE WEAKNESS; MYALGIA; NECROSIS; NECROTIZING ARTERITIS; NECROTIZING ENTEROCOLITIS; OVARY CANCER; PANCREAS CANCER; PARESTHESIA; PERIPHERAL EDEMA; PSEUDOCELLULITIS; PUBLICATION; RADIATION DERMATITIS; RAYNAUD PHENOMENON; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STABLE ANGINA PECTORIS; T CELL LYMPHOMA; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE; VASCULITIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; HUMANS; NEOPLASMS; RISK FACTORS; THROMBOSIS; VASCULAR DISEASES;

EID: 57049112847     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802374262     Document Type: Review

References (65)

1. El Karak F, Flechon A. Gemcitabine in bladder cancer. Expert Opin Pharmacother 2007;8:3251-6
2. Package insert of gemcitabine HCl (GemzarTM) for injection. Eli Lilly and Company. Literature revised August 8, 2008
3. NIH. 1999 recommendations for the safe handling of cytotoxic drugs. US. Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH Publication No. 92-2621. 2002
4. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007;34:347-53
5. Schwartz JD, Simantov R. Thrombosis and malignancy: pathogenesis and prevention. In Vivo 1998;12:619-24
6. Sørensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-73
7. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91
8. Nadir Y, Hoffman R, Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004;8:E4
9. Zecchina G, Ghio P, Bosio S, et al. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007;8:264-7
10. Kuenen BC, Levi M, Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003;21:2192-8
11. Vokurka J. Effect of gemcitabine on vascular endothelium in the rat. Acta Vet Brno 2004;73:201-4
12. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34
13. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;113:772-8
14. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005;103:994-9
15. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublers in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91
16. Duvic M, Talpar R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51-8
17. Kalapura T, Krishnamurthy M, Reddy CV. Acute myocardial infarction following gemcitabine therapy - a case report. Angiology 1999;50:1021-5
18. Bdair FM, Graham SP, Smith PF, et al. Gemcitabine and acute myocardial infarction - a case report. Angiology 2006;57:367-71
19. Naitoh N, Funazaki T, Watanabe S, et al. Acute myocardial infarction induced by lung cancer chemotherapy after radiation of left lung. Gan To Kagaku Ryoho 2005;32:265-7
20. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007;8:634-41
21. Teixeira L, Debourdeau P, Zammit C, et al. Gemcitabine-induced thrombotic microangiopathy. Presse Med 2002;31:740-2
22. Serke S, Riess H, Oettle H, et al. Elevated reticulocyte count - a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 1999;79:1519-21
23. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100:2664-70
24. Fung MC, Storniolo AM, Nguyen B, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-32
25. Lewin SN, Mutch DG, Whitcomb BP, et al. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 2005;97:228-33
26. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002;40:E16
27. De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol 2008;87:495-6
28. Kalra N, Kad R, Osama S. Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma. Int J Clin Oncol 2007;12:385-7
29. Müller S, Schütt P, Bojko P, et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 2005;84:110-4
30. Schmidt A, Schwella N, Helmchen U, et al. A 42 year old patient with bilateral loss of sight and hypertension. Internist (Berl) 2008;49:989-94
31. Flombaum CD, Mouradian JA, Casper ES, et al. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999;33:555-62
32. Desramé J, Duvic C, Bredin C, et al. Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature. Rev Med Interne 2005;26:179-88
33. Vénat-Bouvet L, Ly K, Szelag JC, et al. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. Anticancer Drugs 2003;14:829-32
34. Barceló R, López-Vivanco G, Mañé JM, et al. Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases. Ann Oncol 2000; 11:1191-4
35. Buch RS, Geisbüsch R, Kunkel M. Acral ischemia as a rare paraneoplastic syndrome in the terminal phase of mouth floor carcinoma. Mund Kiefer Gesichtschir 2002;6:331-5
36. Blaise S, Appeltants H, Carpentier PH, et al. Digital ischaemia and gemcitabine. Two new cases. J Mal Vasc 2005;30:53-7
37. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 2003;30:1341-3
38. Voorburg AM, van Beek FT, Slee PH, et al. Vasculitis due to gemcitabine. Lung Cancer 2002;36:203-5
39. D'Alessandro V, Errico M, Varriale A, et al. Case report: acro-necrosis of the upper limbs caused by gemcitabine therapy. Clin Ther 2003;154:207-10
40. Birlik M, Akar S, Tuzel E, et al. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder. J Cancer Res Clin Oncol 2004;130:122-5
41. Geisler JP, Schraith DF, Manahan KJ, et al. Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer. Gynecol Oncol 2004;92:705-7
42. Barlési F, Villani P, Doddoli C, et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85-91
43. Joerger M, Gunz A, Speich R, et al. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 2002;132:17-20
44. De Pas T, Curigliano G, Franceschelli L, et al. Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 2001;12:1651-2
45. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91
46. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998;114:1779-81
47. Biswas S, Nik S, Corrie PG. Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol) 2004;16:577-9
48. Bonnichon A, Vedrine L, Aletti M, et al. Favorable outcome of gemcitabine-induced acute respiratory distress syndrome. Rev Pneumol Clin 2007;63:379-83
49. Pulkkanen K, Kataja V, Johansson R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother 2003;15:287-9
50. Azzoli CG, Miller VA, Ng KK, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol 2003;26:247-51
51. Tan DH, Bunce PE, Liles WC, et al. Gemcitabine-related "pseudocellulitis": report of 2 cases and review of the literature. Clin Infect Dis 2007;45:e72-6
52. Schwartz BM, Khuntia D, Kennedy AW, et al. Gemcitabine induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol 2003;91:421-2
53. Parc C. Purtscher-like retinopathy as an initial presentation of a thrombotic microangiopathy associated with antineoplastic therapy. Am J Hematol 2007;82:486-8
54. Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch Ophthalmol 2000;118:726-7
55. Vieillot S, Pouessel D, de Champfleur NM, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol 2007;18:608-9
56. Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist 2007;12:1332-5
57. Connolly RM, Doherty CP, Beddy P, et al. Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer 2007;56:459-63
58. Rangi PS, Partridge WJ, Newlands ES, et al. Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology 2005;47:586-90
59. Russell MT, Nassif AS, Cacayorin ED, et al. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 2001;19:129-32
60. Cavdar C, Toprak O, Oztop I, et al. Bilateral renal infarction in a patient with lung carcinoma treated with cisplatin and gemcitabine. Renal Fail 2007;29:923-5
61. Mercié P, Faure I, Viallard JF, et al. Splenic vascular occlusion in the course of pancreatic cancer. Rev Med Interne 2000;21:628-31
62. Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003;48:1804-8
63. Kagohashi K, Funayama Y, Satoh H, et al. Fatal hepatic failure due to gemcitabine and vinorelbine. Ann Oncol 2003;14:960
64. Matsuda M, Watanabe G, Mine S, et al. Fatal liver failure associated with gemcitabine hydrochloride therapy. Gan To Kagaku Ryoho 2008;35:157-9
65. Dobbie M, Hofer S, Oberholzer M, et al. Veno-occlusive disease of the liver induced by gemcitabine. Ann Oncol 1998;9:681